Moclobemide Pharmaceutical API
Pharmaceutical Premium
Pharmaceutical API

Moclobemide

High-purity pharmaceutical grade Moclobemide API manufactured to meet stringent USP/EP specifications for antidepressant medication production. Our pharmaceutical-grade Moclobemide delivers exceptional quality and consistency for critical pharmaceutical applications.

  • USP/EP Compliant Grade
  • High Purity (>99.5%)
  • RIMA Antidepressant
  • GMP Certified Manufacturing
  • Reliable Supply Chain
  • Complete Documentation
Request Quote Technical Support

Technical Specifications

Chemical Formula: C13H17ClN2O2
CAS Number: 71320-77-9
EINECS Number: 275-447-4
Molecular Weight: 268.74 g/mol
Physical State: White to off-white crystalline powder
Purity (HPLC): ≥99.0% (USP/EP Grade)
Melting Point: 156-160°C
pH (1% solution): Not applicable (poorly soluble)
Loss on Drying: ≤0.5%
Residue on Ignition: ≤0.1%
Heavy Metals (as Pb): ≤10 ppm
Related Substances: ≤1.0% (total impurities)
Storage Conditions: Store below 25°C, protect from light
Shelf Life: 3 years from date of manufacture
Packaging Options: 25kg drums, 100kg containers

Applications

Major Depressive Disorder
RIMA Antidepressant
MAO-A Inhibitor
Anxiety Treatment
Psychiatric Research
Hospital Psychiatry
Pharmaceutical Manufacturing
Neuropharmacology
CNS Research
Clinical Trials
Regulatory Submissions
Reference Standards

Industry-Specific Grades

DRAVYOM offers specialized Moclobemide grades tailored for specific psychiatric pharmaceutical requirements, ensuring optimal performance and regulatory compliance across diverse antidepressant therapy applications.

USP Grade (United States Pharmacopeia)
Purity: ≥99.0% (HPLC) Loss on Drying: ≤0.5% Heavy Metals: ≤10 ppm Application: FDA-compliant formulations
EP Grade (European Pharmacopoeia)
Purity: ≥99.0% (HPLC) Melting Point: 156-160°C Related Substances: ≤1.0% Application: EU regulatory submissions
Psychiatric Research Grade
Purity: ≥99.5% (HPLC) Enhanced bioavailability Low endotoxin levels Application: CNS research
Reference Standard Grade
Purity: ≥99.8% (HPLC) Certified Analysis: COA included Traceability: NIST traceable Application: Analytical standards

Quality Standards

DRAVYOM's Moclobemide API is manufactured under stringent quality control protocols, meeting international pharmaceutical standards including USP, EP, and cGMP specifications. Our pharmaceutical-grade production ensures consistent performance and regulatory compliance.

cGMP Certified Manufacturing
USP/EP Grade Specifications
≥99.0% HPLC Purity
Advanced Analytical Testing
Light-Protected Processing
Batch-to-Batch Consistency
Comprehensive Certificate of Analysis
Temperature-Controlled Logistics

Advanced Chemical Properties & Performance

Pharmaceutical Grade Moclobemide exhibits exceptional chemical properties essential for psychiatric applications. Its optimal molecular structure and reversible MAO-A inhibition characteristics ensure reliable performance in demanding antidepressant formulations.

Molecular Properties
Molecular Weight: 268.31 g/mol
Molecular Formula: C13H17ClN2O2
LogP (Octanol/Water): 1.5
Solubility (Water): Freely soluble
Physical Properties
Melting Point: 156-160°C
Appearance: White to off-white crystalline powder
Crystal Form: Anhydrous Form I
Bulk Density: 0.40-0.50 g/cm³
Pharmaceutical Properties
Bioavailability: ~95%
Protein Binding: 50%
Half-life: 2-4 hours
Mechanism: Reversible MAO-A inhibition
Quality Specifications
Purity (HPLC): ≥99.0%
Loss on Drying: ≤0.5%
Related Substances: ≤1.0%
Heavy Metals: ≤10 ppm
Stability Properties
Shelf Life: 3 years (unopened)
Storage Temperature: 15-25°C
Light Sensitivity: Store in light-resistant containers
Moisture Sensitivity: Store in dry conditions

Performance Characteristics

Detailed performance metrics demonstrate Moclobemide superiority in psychiatric applications with exceptional MAO-A inhibition selectivity, rapid onset, and therapeutic efficacy across diverse mental health treatment protocols.

MAO-A Selectivity

Reversible and selective MAO-A inhibition

Enhanced serotonin availability
Rapid Onset

Quick therapeutic response initiation

Faster mood improvement
Tablet Integrity

Excellent compression and stability

Superior pharmaceutical quality
Safety Profile

Minimal dietary restrictions required

Improved patient compliance
Clinical Efficacy

Proven efficacy in depression treatment

FDA-approved therapeutic performance
Formulation Stability

Stable across various formulation types

Versatile pharmaceutical applications

Safety Information

Pharmaceutical active ingredient requiring careful handling protocols. Handle in controlled environments with appropriate ventilation systems. Use proper personal protective equipment and follow established safety protocols for psychoactive compounds.

CNS Active Compound
Controlled Handling Required
Specialized PPE Required

Storage & Handling

Store in tightly closed, light-resistant containers in a cool, dry place away from direct sunlight. Maintain controlled room temperature storage and ensure protection from moisture and humidity to preserve pharmaceutical quality and potency.

Controlled room temperature (15-25°C)
Protect from light
Light-resistant containers
Store in dry conditions

Chemical Mechanisms & Reaction Pathways

Moclobemide exhibits selective monoamine oxidase-A inhibition and reversible enzyme binding, enabling precise psychiatric applications with enhanced mood elevation and reduced dietary restrictions compared to non-selective MAOIs.

MAO-A Selective Inhibition

Reversible inhibition of monoamine oxidase type A

Increases serotonin, norepinephrine, and dopamine levels
Reversible Binding

Competitive and reversible enzyme inhibition

Reduced tyramine interaction risk
RIMA Mechanism

Reversible Inhibitor of Monoamine oxidase-A activity

Safer MAOI therapeutic profile
Neurotransmitter Enhancement

Selective enhancement of mood-regulating neurotransmitters

Improved antidepressant efficacy

Regulatory Compliance & Documentation

Comprehensive regulatory compliance ensures global pharmaceutical access with complete documentation packages supporting international standards and psychiatric pharmaceutical regulatory requirements.

USP Specifications

United States Pharmacopeia psychiatric pharmaceutical grade standards compliance

EP Standards

European Pharmacopoeia specifications for MAOI pharmaceutical manufacturing

cGMP Manufacturing

Current Good Manufacturing Practice certified psychiatric API production

ICH Guidelines

International Conference on Harmonisation psychiatric quality standards

DMF Support

Drug Master File documentation for psychiatric regulatory submissions

Safety Documentation

Complete psychiatric safety and handling documentation package

Technical Support & Value-Added Services

DRAVYOM's psychiatric pharmaceutical development team provides comprehensive formulation support, MAOI handling guidance, and regulatory support to optimize Moclobemide performance in your psychiatric pharmaceutical applications.

Formulation Development
  • Tablet formulation optimization
  • Immediate release formulation
  • Bioavailability enhancement strategies
  • Stability enhancement guidance
Analytical Services
  • Certificate of Analysis verification
  • MAOI API impurity profiling
  • Stability method validation
  • Enzyme inhibition studies
Technical Support
  • Psychiatric API handling consultation
  • cGMP compliance for CNS manufacturing
  • MAOI safety protocols
  • Regulatory documentation support
Supply Solutions
  • Specialized psychiatric packaging
  • Temperature-controlled logistics
  • Emergency psychiatric supply
  • Global pharmaceutical distribution

Environmental Impact & Sustainability

Our Moclobemide production emphasizes environmental responsibility through sustainable psychiatric pharmaceutical manufacturing practices, waste minimization, and comprehensive environmental impact management for MAOI API operations.

Waste Minimization

Optimized synthesis with minimal psychiatric pharmaceutical waste generation

Water Treatment

Advanced pharmaceutical wastewater treatment and recycling systems

Green Chemistry

Environmentally conscious psychiatric API synthesis with emission controls

Safe Disposal

Comprehensive guidance for psychiatric pharmaceutical waste management

ISO 14001

Environmental management system certified pharmaceutical production

Carbon Footprint

Reduced carbon footprint through psychiatric API process optimization

Manufacturing Excellence & Quality Control

DRAVYOM's specialized psychiatric pharmaceutical manufacturing facility employs advanced synthesis technology and continuous monitoring systems to ensure consistent Moclobemide quality and potency across all production batches.

Production Process

Advanced synthesis and purification in controlled psychiatric environment

Multi-stage crystallization for psychiatric pharmaceutical grade quality
Quality Testing

Comprehensive analytical testing including MAOI activity analysis

HPLC verification and enzyme inhibition analysis
Quality Systems

ISO 9001:2015 quality management with psychiatric pharmaceutical accreditation

Specialized psychiatric API quality systems
Packaging Control

Specialized light-resistant containers with controlled atmosphere

Light and moisture protection systems

Market Applications & Performance Data

Comprehensive psychiatric pharmaceutical development data demonstrating Moclobemide effectiveness across diverse therapeutic applications with quantified performance metrics and MAOI development validations.

Psychiatric Manufacturing
Bioavailability: 60-80% oral bioavailability Stability: Light and heat sensitive API Purity: >99.5% psychiatric grade
Clinical Applications
Efficacy: Proven depression and social anxiety treatment Safety: Safer MAOI profile with reduced interactions Regulatory: Psychiatric approvals in multiple regions
Manufacturing Capabilities
Capacity: Controlled psychiatric production batches Consistency: <0.3% batch-to-batch variation Compliance: 100% psychiatric cGMP adherence

DRAVYOM Competitive Advantages

Psychiatric Expertise

Specialized psychiatric manufacturing with ultra-low impurities and exceptional MAOI pharmaceutical performance

Reliable Supply

Guaranteed availability with specialized inventory management and psychiatric-grade production scheduling

MAOI Expertise

Dedicated psychiatric pharmaceutical development team with MAOI formulation expertise

Quality Assurance

Comprehensive certificates with complete analytical data and psychiatric handling documentation

Global Standards

International compliance with USP, EP, and ICH specifications for worldwide psychiatric pharmaceutical acceptance

Partnership Approach

Collaborative relationships with psychiatric pharmaceutical companies and custom MAOI API development